Trial Profile

Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALRN 6924 (Primary) ; Cytarabine
Indications Acute myeloid leukaemia; CNS cancer; Hepatoblastoma; Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Retinoblastoma; Rhabdoid tumour; Solid tumours; Teratoma
Focus Adverse reactions

Most Recent Events

10 Jan 2025 According to Rein Therapeutics media release, Aileron Therapeutics announces rebranding to Rein Therapeutics
16 Aug 2023 Status changed from discontinued to completed.
20 Jun 2023 Planned End Date changed from 1 Jun 2023 to 1 Sep 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com